Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
309 articles with Sunovion Pharmaceuticals Inc.
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo
Sunovion Enters Into License Agreement For Three Approved Treatment Options For People With COPD In The U.S.
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis
Demi Lovato, Sunovion And Leading Advocacy Organizations Launch The Be Vocal Collection In Partnership With Getty Images To Encourage The Realistic Portrayal Of Mental Health
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia
The American College of Chest Physicians And Sunovion Announce Strategic Initiative Focused On The Importance Of Drug Delivery In The Management Of COPD
Sunovion Announces FDA Filing Acceptance Of New Drug Application For SUN-101/Eflow For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sunovion Announces Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD
Massachusetts' Sunovion Swallows Up Cynapsus in $624 Million Deal, Gains Experimental Parkinson's Drug
Sunovion Pharmaceuticals Inc. Hands On! Annual Community Service Program Contributes More Than 20,000 Employee Volunteer Hours Over Five Years To Support Youth Organizations And Community Relief Efforts
Sunovion Pharmaceuticals Inc. Announces Publication Of Data Evaluating Dose Escalation Of Latuda (Lurasidone HCL) In The Treatment Of Schizophrenia
Sunovion Pharmaceuticals Inc. Submits New Drug Application For SUN-101/Eflow To The FDA For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)
Sunovion Pharmaceuticals Inc. Announces Results Of Phase III Long-Term Safety Study Showing SUN-101/Eflow® (Glycopyrrolate) Was Well-Tolerated In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (C
Sunovion Pharmaceuticals Inc.Announces Publication Of Data Evaluating The Long-Term Safety And Tolerability Of Latuda (Lurasidone Hcl) In The Treatment Of Bipolar Depression
Sunovion Pharmaceuticals Inc. Announces Health Outcomes Data On Exacerbation-Related Hospitalizations That Support The Use Of Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society